chr16-68738295-A-C

Variant summary

Our verdict is Pathogenic. The variant received 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong

The NM_004360.5(CDH1):​c.49-2A>C variant causes a splice acceptor, intron change. The variant was absent in control chromosomes in GnomAD project. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).

Frequency

Genomes: not found (cov: 32)

Consequence

CDH1
NM_004360.5 splice_acceptor, intron

Scores

1
4
2
Splicing: ADA: 1.000
2

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:2

Conservation

PhyloP100: 4.40

Publications

3 publications found
Variant links:
Genes affected
CDH1 (HGNC:1748): (cadherin 1) This gene encodes a classical cadherin of the cadherin superfamily. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate the mature glycoprotein. This calcium-dependent cell-cell adhesion protein is comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. Mutations in this gene are correlated with gastric, breast, colorectal, thyroid and ovarian cancer. Loss of function of this gene is thought to contribute to cancer progression by increasing proliferation, invasion, and/or metastasis. The ectodomain of this protein mediates bacterial adhesion to mammalian cells and the cytoplasmic domain is required for internalization. This gene is present in a gene cluster with other members of the cadherin family on chromosome 16. [provided by RefSeq, Nov 2015]
CDH1 Gene-Disease associations (from GenCC):
  • blepharocheilodontic syndrome 1
    Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Ambry Genetics, Illumina, Labcorp Genetics (formerly Invitae), G2P
  • CDH1-related diffuse gastric and lobular breast cancer syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, G2P
  • hereditary breast carcinoma
    Inheritance: AD Classification: DEFINITIVE Submitted by: Ambry Genetics
  • hereditary diffuse gastric adenocarcinoma
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Ambry Genetics, Orphanet
  • cleft soft palate
    Inheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
  • orofacial cleft 3
    Inheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
  • blepharocheilodontic syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • familial ovarian cancer
    Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 12 ACMG points.

PVS1
Splicing +-2 bp (donor or acceptor) variant, product NOT destroyed by NMD, known LOF gene, truncates exone, which is 0.043412607 fraction of the gene. Cryptic splice site detected, with MaxEntScore 7.9, offset of 21, new splice context is: tctcctcttggctctgccAGgag. Cryptic site results in inframe change. If cryptic site found is not functional and variant results in exon loss, it results in frameshift change.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 16-68738295-A-C is Pathogenic according to our data. Variant chr16-68738295-A-C is described in ClinVar as Pathogenic. ClinVar VariationId is 1744170.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CDH1NM_004360.5 linkc.49-2A>C splice_acceptor_variant, intron_variant Intron 1 of 15 ENST00000261769.10 NP_004351.1 P12830-1A0A0U2ZQU7B3GN61
CDH1NM_001317184.2 linkc.49-2A>C splice_acceptor_variant, intron_variant Intron 1 of 14 NP_001304113.1 P12830-2B3GN61
CDH1NM_001317185.2 linkc.-1567-2A>C splice_acceptor_variant, intron_variant Intron 1 of 15 NP_001304114.1 P12830B3GN61Q9UII7
CDH1NM_001317186.2 linkc.-1771-2A>C splice_acceptor_variant, intron_variant Intron 1 of 14 NP_001304115.1 P12830B3GN61

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CDH1ENST00000261769.10 linkc.49-2A>C splice_acceptor_variant, intron_variant Intron 1 of 15 1 NM_004360.5 ENSP00000261769.4 P12830-1
CDH1ENST00000422392.6 linkc.49-2A>C splice_acceptor_variant, intron_variant Intron 1 of 14 1 ENSP00000414946.2 P12830-2
CDH1ENST00000566612.5 linkn.49-2A>C splice_acceptor_variant, intron_variant Intron 1 of 14 1 ENSP00000454782.1 H3BNC6
CDH1ENST00000566510.5 linkn.49-2A>C splice_acceptor_variant, intron_variant Intron 1 of 14 5 ENSP00000458139.1 H3BVI7

Frequencies

GnomAD3 genomes
Cov.:
32
GnomAD4 exome
Cov.:
29
GnomAD4 genome
Cov.:
32

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Pathogenic:1
Jun 20, 2022
Clinical Genetics Laboratory, Skane University Hospital Lund
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hereditary cancer-predisposing syndrome Pathogenic:1
May 19, 2025
Ambry Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.49-2A>C intronic pathogenic mutation results from an A to C substitution two nucleotides upstream from coding exon 2 in the CDH1 gene. This mutation has been described in a family affected with hereditary diffuse gastric cancer (HDGC) as well as several other types of cancer, and was observed to segregate with disease in three family members (More H et al. Hum. Mutat. 2007; 28:203-211). In addition, another mutation at the same nucleotide position (c.49-2A>G) has been reported in two unrelated individuals with HDGC (Richards FM et al. Hum. Mol. Genet. 1999; 8:607-10; Moran CJ et al. Eur J Surg Oncol 2005; 31:259-64). In addition to the clinical information presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Uncertain
0.10
D
BayesDel_noAF
Benign
-0.090
CADD
Pathogenic
34
DANN
Uncertain
0.97
Eigen
Pathogenic
0.86
Eigen_PC
Uncertain
0.64
FATHMM_MKL
Uncertain
0.87
D
PhyloP100
4.4
GERP RS
4.8
Mutation Taster
=0/100
disease causing

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
1.0
dbscSNV1_RF
Pathogenic
0.92
SpliceAI score (max)
0.99
Details are displayed if max score is > 0.2
DS_AG_spliceai
0.79
Position offset: 23
DS_AL_spliceai
0.99
Position offset: 2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1060501226; hg19: chr16-68772198; API